Table 2. Clinico-pathological characteristics of 195 HNSCC included in the second cohort and association with PD-L1 expression.
| Total number (n) | PD-L1 high | PD-L1 low | PD-L1 negative | p-value | |
|---|---|---|---|---|---|
| All HNSCC cases | 195 (100%) | 54 (27.69%) | 111 (56.92%) | 30 (15.38%) | |
| Age | p=0.044† | ||||
| ≤50 years | 29 (14.87%) | 13 (44.83%) | 15 (51.72%) | 1 (3.45%) | |
| 51-60 years | 50 (25.64%) | 16 (32.00%) | 24 (48.00%) | 10 (20.00%) | |
| > 60 years | 116 (59.49%) | 25 (21.55%) | 72 (62.07%) | 19 (16.38%) | |
| Median age [years] | 62 | ||||
| Mean age [years] | 62.41 | ||||
| Age range [years] | 27-87 | ||||
| Gender | p=0.673† | ||||
| Female | 53 (27.18%) | 17 (32.08%) | 29 (54.72%) | 7 (13.21%) | |
| Male | 142 (72.82%) | 37 (26.06%) | 82 (57.75%) | 23 (16.20%) | |
| Follow-up | |||||
| Mean follow-up [days] | 856 | ||||
| Median follow-up [days] | 791 | ||||
| Range follow-up [days] | 1-2566 | ||||
| Tobacco use | p=0.798† | ||||
| Non-smokers | 23 (11.79%) | 7 (30.43%) | 12 (52.17%) | 4 (17.39%) | |
| Smokers (current and former) | 114 (58.46%) | 30 (26.32%) | 68 (59.65%) | 16 (14.04%) | |
| Unknown smoking status | 58 (29.74%) | 17 (29.31%) | 31 (53.45%) | 10 (17.24%) | |
| Alcohol consumption | p=0.147† | ||||
| No alcohol | 51 (26.15%) | 17 (33.33%) | 30 (58.82%) | 4 (7.84%) | |
| Ocasional alcohol | 28 (14.36%) | 5 (17.86%) | 19 (67.86%) | 4 (14.29%) | |
| Alcoholic (current and former) | 51 (26.15%) | 12 (23.53%) | 27 (52.94%) | 12 (23.53%) | |
| Unknown alcohol consumption | 65 (33.33%) | 20 (30.77%) | 35 (53.85%) | 10 (15.38%) | |
| HPV status | p=0.916† | ||||
| Negative | 179 (91.79%) | 50 (27.93%) | 102 (56.98%) | 27 (15.08%) | |
| Positive | 16 (8.21%) | 4 (25.00%) | 9 (56.25%) | 3 (18.75%) | |
| Localization | p=0.026† | ||||
| Oral cavity | 54 (27.69%) | 17 (31.48%) | 27 (50.00%) | 10 (18.52%) | |
| Oropharnyx | 79 (40.51%) | 20 (25.32%) | 46 (58.23%) | 13 (16.46%) | |
| hypopharnyx | 18 (9.23%) | 8 (44.44%) | 5 (27.78%) | 5 (27.78%) | |
| larynx | 44 (22.56%) | 9 (20.45%) | 33 (75.00%) | 2 (4.55%) | |
| T-stage | p=0.138† | ||||
| T1 | 54 (27.69%) | 8 (14.81%) | 36 (66.67%) | 10 (18.52%) | |
| T2 | 64 (32.82%) | 20 (31.25%) | 34 (53.13%) | 10 (15.63%) | |
| T3 | 48 (24.62%) | 13 (27.08%) | 30 (62.5%) | 5 (10.42%) | |
| T4 | 25 (12.82%) | 11 (44.00%) | 10 (40%) | 4 (16%) | |
| Tx | 4 (2.05%) | 2 (50.00%) | 1 (25.00%) | 1 (25.00%) | |
| Lymph node involvement | p=0.115† | ||||
| N0 | 86 (44.10%) | 19 (22.09%) | 54 (62.79%) | 13 (15.12%) | |
| N1 | 29 (14.87%) | 6 (20.69%) | 20 (68.97%) | 3 (10.34%) | |
| N2 | 69 (35.38%) | 27 (39.13%) | 29 (42.03%) | 13 (18.84%) | |
| N3 | 2 (1.03%) | 1 (50.00%) | 1 (50.00%) | 0 (0.00%) | |
| Nx | 9 (4.62%) | 1 (11.11%) | 7 (77.78%) | 1 (11.11%) | |
| Distant metastases | p=0.025† | ||||
| M0 | 188 (96.41%) | 49 (26.06%) | 110 (58.51%) | 29 (15.43%) | |
| M1 | 7 (3.59%) | 5 (71.43%) | 1 (14.29%) | 1 (14.29%) | |
| Grading | p=0.697† | ||||
| G1 | 7 (3.59%) | 1 (14.29%) | 4 (57.14%) | 2 (28.57%) | |
| G2 | 107 (54.87%) | 29 (27.10%) | 63 (58.88%) | 15 (14.02%) | |
| G3 | 45 (23.08%) | 15 (33.33%) | 23 (51.11%) | 7 (15.56%) | |
| n/a | 36 (18.46%) | 9 (25.00%) | 21 (58.33%) | 6 (16.67%) | |
| Lymphatic invasion | p=0.465† | ||||
| L0 | 88 (45.13%) | 24 (27.27%) | 46 (52.27%) | 18 (20.45%) | |
| L1 | 22 (11.28%) | 7 (31.82%) | 13 (59.09%) | 2 (9.09%) | |
| n/a | 85 (43.59%) | 23 (27.06%) | 52 (61.18%) | 10 (11.76%) | |
| Vascular invasion | p=0.388† | ||||
| V0 | 96 (49.23%) | 26 (27.08%) | 51 (53.13%) | 19 (19.79%) | |
| V1 | 8 (4.10%) | 4 (50.00%) | 3 (37.50%) | 1 (12.50%) | |
| n/a | 91 (46.67%) | 24 (26.37%) | 57 (62.64%) | 10 (10.99%) | |
| Extracapsular expansion | p=0.235† | ||||
| ece- | 73 (37.44%) | 21 (28.77%) | 40 (54.79%) | 12 (16.44%) | |
| ece+ | 28 (14.36%) | 13 (46.43%) | 11 (39.29%) | 4 (14.29%) | |
| n/a | 94 (48.21%) | 20 (21.28%) | 60 (63.83%) | 14 (14.89%) | |
| Surgical margin | p=0.942† | ||||
| R0 | 136 (69.74%) | 41 (30.15%) | 74 (54.41%) | 21 (15.44%) | |
| R1 | 10 (5.13%) | 3 (30.00%) | 6 (60.00%) | 1 (10.00%) | |
| R2 | 3 (1.54%) | 1 (33.33%) | 2 (66.67%) | 0 (0.00%) | |
| n/a | 46 (23.59%) | 9 (19.57%) | 29 (63.04%) | 8 (17.39%) |
†X2-test (Pearson)